Association ofCYP2C19*2and associated haplotypes with lower norendoxifen concentrations in tamoxifen‐treatedAsianbreast cancer patients
- 8 March 2016
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 81 (6) , 1142-1152
Abstract
Aim: The aim was to examine the influence ofCYP2C19variants and associated haplotypes on the disposition of tamoxifen and its metabolites, particularly norendoxifen (NorEND), inAsianpatients with breast cancer.Methods: Sixty‐sixCYP2C19polymorphisms were identified in healthy Asians (n = 240), of which 14 were found to be tightly linked withCYP2C19*2,CYP2C19*3andCYP2C19*17. These 17 SNPs were further genotyped inAsianbreast cancer patients receiving tamoxifen (n = 201). Steady‐state concentrations of tamoxifen and its metabolites were quantified using liquid chromatography–mass spectrometry. Non‐parametric tests and regression methods were implemented to evaluate genotypic–phenotypic associations and haplotypic effects of the SNPs.Results: CYP2C19functional polymorphisms and their linked SNPs were not significantly associated with plasma concentrations of tamoxifen and its main metabolites N‐desmethyltamoxifen, (Z)‐4‐hydroxytamoxifen and (Z)‐Endoxifen. However,CYP2C19*2and its seven linked SNPs were significantly associated with lower NorEND concentrations, MRNorEND/NDDMand MRNorEND/(Z)‐END. Specifically, patients carrying theCYP2C19*2variant allele A had significantly lower NorEND concentrations [median (range), GGvs. GAvs. AA: 1.51 (0.38–3.28)vs. 1.28 (0.30–3.36)vs. 1.15 ng ml−1(0.26–2.45,P = 0.010)] as well as significantly lower MRNorEND/(Z)‐END[GGvs. GAvs. AA: 9.40 (3.27–28.35)vs. 8.15 (2.67–18.9)vs. 6.06 (4.47–14.6),P < 0.0001] and MRNorEND/NDDM[GGvs. GAvs.AA: 2.75 (0.62–6.26)vs.2.43 (0.96–4.18)vs.1.75 (1.10–2.49),P < 0.00001].CYP2C19H2 haplotype, which includedCYP2C19*2, was also significantly associated with lower NorEND concentrations (P = 0.0020), MRNorEND/NDDM(P < 0.0001) and MRNorEND/(Z)‐END(P < 0.0001), indicating significantly lower formation rates of NorEND.Conclusion: These data highlight the potential relevance ofCYP2C19pharmacogenetics in influencing NorEND concentrations in tamoxifen‐treated patients, which may influence treatment outcomes.Keywords
This publication has 42 references indexed in Scilit:
- SULT1A1 , CYP2C19 and Disease-Free Survival in early Breast Cancer Patients Receiving TamoxifenPharmacogenomics, 2011
- The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agentsBreast Cancer Research and Treatment, 2011
- Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patientsBritish Journal of Clinical Pharmacology, 2011
- CYP2C19haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazoleJournal of Clinical Pharmacy and Therapeutics, 2009
- Polymorphism of human cytochrome P450 enzymes and its clinical impactDrug Metabolism Reviews, 2009
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2005
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002